Huperria serrata extract is a product extracted from Melaleuca and dried whole plants as raw materials. Commercially labeled extracts are usually standardized to contain 1% Huperzine A.
The folk use its whole herb to treat carbuncle swollen poison, snake bites, burns and scalds. Huperzine A, the alkaloid component in the dry-bed tower, is a potent and reversible cholinesterase inhibitor, which can improve the functional decline of senile memory, and can significantly improve the memory, cognition and behavior of patients with Alzheimer's disease Ability is a promising drug for the treatment of Alzheimer's disease. Synthetic Huperzine A is available too.
Plant source: Huperzia serrata
Product Appearance:Brown to white powder
Active Ingredient:Huperzine A
Specifications: Huperzine A 1%--99%
Molecular Weight: 242.32
Molecular formula: C15H18N2O
Storage: Low temperature storage (no more than 20 ℃)
Huperzine A is a cholinesterase inhibitor, which selective inhibitory affect on true ChE and and is easy to pass through the blood-brain barrier. Extracted Huperzine A can promoe memory reproduction and enhancing memory retention.
PHYSICAL / CHEMICAL/ MICROBIOLOGICAL
TASTE & ODOR
100% pass 80 mesh or customized 200mesh
MOULD & YEAST
Cool, Ventilate & Dry
Customized specification also can be achieved
The Huperria serrata herb are percolated with 1-1.5% hydrochloric acid, adjusted the solution to pH 6. Flow the fluid through macroporous resin to get selected solution, washed with water and eluted with 50% ethanol, then concentrate, dried, and pulverize into powder. Dilute with ethanol, concentration the solution then dry and crush. Finally, Huperria serrata extract is done.
1.Huperzine A is a highly selective anticholinesterase inhibitor that can significantly promote cholinergic transmission at nerve junctions
2. Huperzine A was used in the early treatment of myasthenia gravis. Modern pharmacological studies have shown that Huperzine A is a good medicine to cure Alzheimer's disease (senile memory impairment).
It is reported that there are more than one million people with Alzheimer’s disease or AD in the United States, and 25% of Alzheimer’s patients in Japan. A survey report in Shanghai shows that 4.5% of people over 55 in the area suffer from severe dementia and 14.4% have mild dementia. Dementia, so the market prospects of Melaleuca extract and related products are prospective.
Patients with epilepsy, renal insufficiency, mechanical intestinal obstruction, urinary tract obstruction, angina pectoris, bradycardia and bronchial asthma shall not use.